Intravitreal bevacizumab (Avastin^®) for radiation retinopathy neovascularization

Treatment of radiation retinopathy following plaque brachytherapy for choroidal melanoma

“…Another patient with radiation retinopathy following stereotactic radiotherapy was treated with intravitreal bevacizumab after no improvement was seen following panretinal photocoagulation [19]. Retinal neovascularization disappeared 2 days after injection, and a decrease in vitreous hemorrhage was observed.…”

Choroidal melanoma treated with stereotactic fractionated radiotherapy and prophylactic intravitreal bevacizumab: The Dunedin Hospital experience

“…Our findings were limited by the small number of patients and the fact that data were collected retrospectively from patient notes and the study was not a randomised control trial. There was possibly a trend towards delaying retinopathy (albeit not significant) in this study, and there are a few low‐level evidence studies regarding PIB use . Thus, we believe that more studies are needed before we can completely dismiss PIB for treatment and prevention of RR.…”

“…There was possibly a trend towards delaying retinopathy (albeit not significant) in this study, and there are a few low-level evidence studies regarding PIB use. 11,17,18 Thus, we believe that more studies are needed before we can completely dismiss PIB for treatment and prevention of RR.…”

“…There are variable clinical responses when intravitreal bevacizumab is used to treat radiation retinopathy with some studies reporting reduction in haemorrhage, retinal oedema and neovascularisation with either improvement or maintenance of vision . Shah et al .…”

“…15,16 There are variable clinical responses when intravitreal bevacizumab is used to treat radiation retinopathy with some studies reporting reduction in haemorrhage, retinal oedema and neovascularisation with either improvement or maintenance of vision. 11,17,18 Shah et al 19 have explored intravitreal bevacizumab as a means of preventing or reducing the incidence of radiation maculopathy, with a reduced incidence of macular oedema at 2 years. Poku et al's 20 systematic review of the safety of intravitreal bevacizumab showed low rates of adverse events following treatment, and even then, it is unclear if quality of PIB has a role in these reported incidents.…”